Vivjoa (oteseconazole) is an azole antifungal medication used to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females who are not of reproductive potential. RVVC is a condition in which a woman has four or more episodes of vaginal yeast infections in a 12-month period.